Reviva Pharmaceuticals -CW23RVPHWPreferred / convertible
13F holders, Q1 2024 (March 31)5holders
$0.71avg. 13F price*
At the end of Q1 2024, 5 institutions reported holding Reviva Pharmaceuticals -CW23 (RVPHW) in their 13F filings. The largest holders were Arena Investors LP ($56K), Walleye Capital LLC ($21K) and B. Riley Wealth Advisors, Inc. ($17K).
- Company
- Reviva Pharmaceuticals -CW23
- CUSIP
- 76152G118
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $19K |
| Exits | 0 | $0 |
Ownership 5 holders
| Arena Investors LP | — | No change | 85,000 | $56K |
| Walleye Capital LLC | — | No change | 33,718 | $21K |
| B. Riley Wealth Advisors, Inc. | — | New | 11,101 | $17K |
| Walleye Trading LLC | — | No change | 25,727 | $16K |
| UBS Group AG | — | New | 2,382 | $2K |
"% of holder's portfolio" is RVPHW's weight in each manager's 13F, not the share of Reviva Pharmaceuticals -CW23 the manager owns.